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Background: We studied the maximum tolerated dose (MTD) and efﬁcacy of oxaliplatin
added to capecitabine and radiotherapy (Capox-RT) as neoadjuvant therapy for rectal cancer.
Methods: T3-4 rectal cancer patients received escalating doses of oxaliplatin (day 1 and 29)
with a ﬁxed dose of capecitabine of 1000 mg/m2 twice daily (days 1–14, 25–38) added to RT
with 50.4 Gy and surgery after 6–8 weeks. The MTD, determined during phase I, was used in
the subsequent phase II, in which R0 resection rate (a negative circumferential resection
margin) was the primary end point.
Results: Twenty-one patients were evaluable. In the phase I part, oxaliplatin at 85 mg/m2
was established as MTD. In phase II, the main toxicity was grade III diarrhea (18%). All
patients underwent surgery, and 20 patients had a resectable tumor. An R0 was achieved in
17/21 patients, downstaging to T0-2 in 7/21 and a pCR in 2/21.
Conclusion: Combination of Capox-RT has an acceptable acute toxicity proﬁle and a high
R0 resection rate of 81% in locally advanced rectal cancer. However the pCR rate was low.
Key Words: Rectal cancer—Radiotherapy—Oxaliplatin—Capecitabine—Chemoradiation—
Phase I–II study.
Colorectal cancer is a major public health problem
in the Western world and ranks as the third leading
cause of death in both males and females. In 2000,
more than 9000 new colorectal cancer patients were
registered in the Netherlands, of whom 25% had
rectal cancer.1 Surgical resection is the only curative
treatment. However, following potentially curative
resection, local recurrence rate varies between 5 and
40%.2–4 Total mesorectal excision (TME) is now the
standard technique for primary resectable rectal
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cancer and has signiﬁcantly improved local con-
trol.4–6 The cornerstone of the TME technique is the
complete removal of the rectum and mesorectum to
realize free circumferential resection margins. Adam
showed in 1994 that the incidence of local recurrence
5 years after resection will rise from 10–78% in case of
circumferential margin (CRM) involvement.7 So
downstaging before the TME procedure may de-
crease the incidence of CRM involvement and local
recurrence. In the Dutch TME trial, no tumor
downstaging was detected in the week after 5 · 5 Gy.8
A recent Polish trial demonstrated that a radiother-
apy schedule of 50.4 Gy combined with chemother-
apy (5-FU/Leucovorin) followed after 4–6 weeks by
surgery resulted in a significant higher percentage of
downstaging compared with short-term preoperative
radiotherapy of 5 · 5 Gy followed by surgery within 7
days.9 So downstaging is dependent on both the total
radiotherapy dose and the interval between the end of
the radiotherapy and the surgery. In general, to
achieve downstaging this interval needs to be at least
6 weeks and the dose needs to be at least 45 Gy.9
Although the obtained downstaging after neoadju-
vant radiochemotherapy did result in a favorable
prognosis,10 it was not clear until recently whether
the addition of chemotherapy to preoperative radio-
therapy could increase the amount of downstaging
and thus improve local control. The evidence that the
addition of chemotherapy to preoperative radiother-
apy improves local control rates has recently been
shown by two separate trials. The EORTC 22921 trial
has a two by two factorial design and randomized
between preoperative radiotherapy (45 Gy) versus
preoperative chemoradiotherapy (45 Gy combined
with 5-FU/Leucovorin). The results demonstrated an
increased local control rate for the chemoradiation
arm: 91% versus 83%.11,12 A similar result was found
in the French FFCD 9203 study, which randomized
between preoperative radiotherapy (45 Gy) and pre-
operative chemoradiotherapy (45 Gy and 5-FU/
Leucovorin) and which showed local recurrence rates
of 16.5% and 8%, respectively.13 Based on these
studies, prolonged preoperative chemoradiation is
considered the standard treatment for resectable lo-
cally advanced rectal cancers. The EORTC study and
the French study employed 5FU bolus injection
modulated with leucovorin. However 5FU adminis-
tered by continuous infusion or orally (capecitabine/
UFT) may be more effective and less toxic than 5FU
administered by bolus injection.14–16 In parallel, the
results of palliative chemotherapy in advanced colo-
rectal cancer have been substantially improved by the
combination of 5FU with oxaliplatin or irinotecan
(reviewed by Punt17). Both in vivo and in vitro, ox-
aliplatin has been shown to have at least an additive
interaction with radiotherapy in the management of
digestive tract tumors.18–20 Incorporation of those
drugs in combined treatment strategies could sub-
stantially improve the results obtained with bolus
5FU alone in downstaging and R0 resection rates in
patients with locally advanced rectal cancer.
We investigated the combination of capecitabine
and oxaliplatin given concomitantly with radiother-
apy in patients with locally advanced rectal cancer.
The optimal dose of oxaliplatin was ﬁrst established
in a phase I study, and in the following phase II study
the eﬃcacy of this regimen was tested.
PATIENTS AND METHODS
Objectives
The objective of the phase I study was to determine
the maximum tolerated dose (MTD) of oxaliplatin in
combination with a ﬁxed dose of capecitabine and
radiotherapy, and the objective of the phase II study
was to determine the R0 resection rate and patho-
logical complete response rate (pCR).
Eligibility Criteria
Eligibility criteria included histologically docu-
mented adenocarcinoma of the rectum within 15 cm
from the anal sphincter, locally advanced stage T3
(distance to the endopelvic fascia < 2 mm) or T4 tu-
mors based on computed tomography (CT) or mag-
netic resonance imaging (MRI) ﬁndings, performance
status (Eastern Cooperative Oncology Group) 0–2,
age >18 years old, adequate hematological, liver
function, and other laboratory parameters (white
blood cells 3.0 · 109/L, platelets >100 · 109/L, crea-
tinin clearance>50mL/min, bilirubin<1.5 times the
upper limit of the normal range (ULN), and written
informed consent. Patients with reproductive potential
should use adequate contraceptive measures. Patients
were excluded in case of prior chemotherapy and/or
pelvic radiotherapy, acute bowel obstruction without
colostomy, uncontrolled ischemic heart disease,
peripheral neuropathy, or any uncontrolled serious
systemic disease. The protocol was approved by the
local ethics committees of all four participating hos-
pitals. The study was performed within the framework
of the Dutch Colorectal Cancer Group (DCCG).
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TREATMENT
Radiotherapy
All patients received radiation delivered by an
isocentric three- or four-ﬁeld technique, using a linear
accelerator of at least 10 MV. The patients were
treated in either supine or prone position with a full
bladder. The radiation ﬁeld extended superiorly to
the L5/S1 junction and covered inferiorly the obtu-
rator foramina. The minimal inferior border ex-
tended 4–5 cm below the tumor. In case the tumor
was located in the lower third of the rectum, the
perineum was encompassed in the treatment field.
The width of the AP-PA portals had to cover the
lateral pelvic inlet with a margin of 1.5 cm. The entire
sacrum was included with a dorsal margin of 1.5 cm.
Anteriorly, the lateral fields had to encompass the
tumor as determined by barium enema (optional) and
pelvic CT scan. If there was clinical evidence of
involvement of the bladder, the prostate, the cervix or
the uterine body, not only the internal iliac nodes but
also the external iliac nodes were included in the
radiation field. Computerized dosimetry was rou-
tinely performed. Irradiation was delivered 5 days per
week at a dose of 1.8 Gy/day to a total dose of 45 Gy
with a boost to the tumor in 3 fractions of 1.8 Gy to a
total of 50.4 Gy.
Chemotherapy
Capecitabine was administered orally twice daily at
1000 mg/ m2 on days 1–14 and 25–38.
Oxaliplatin was given twice by intravenous infu-
sion over 2 h, on the ﬁrst day of radiotherapy and on
day 29. Oxaliplatin doses were planned at 85, 100,
and 135 mg/m2. Each dose level was to be adminis-
tered to at least three patients. If a dose-limiting
toxicity (DLT) was observed in ‡1 patient, a total of 6
patients had to be treated at that dose level. The
maximum-tolerated dose (MTD) was deﬁned as the
level at which £2 out of 6 patients experienced DLTs
without compromizing radiotherapy and surgery and
was the recommended dose in the phase II study.
Surgery
Surgical resection was performed 6–8 weeks after
completion of the chemoradiation therapy. The
resection was performed according to the principles
of total mesorectal excision as described by Heald2
and Enker.21 These principles include sharp dissec-
tion under direct vision following the lipoma-like
surface of the mesorectum. Proximal transection of
the inferior mesenteric artery was in general per-
formed distal to the collateral between the left colic
artery and branches of the sigmoid artery. Anterior
dissection in male patients was carried out in front of
Denonvilliers fascia. If tumor extended into the
prostate a total exenteration was performed. In
female patients, resection of the posterior vaginal
wall was performed if necessary. A distal mesorectal
margin of 2 cm was considered adequate if bowel
continuity was to be restored.
Pathology
Pathology evaluation was standardized according
to national guideliness. The CRM was assessed
according to the method of Quirke et al.,7 and a
margin of <1 mm from the primary tumor to the
endopelvic fascia is considered positive.
Statistics
Twenty patients were to be included at the MTD to
detect with a power of 80% a R0 resectability rate of
>80% (with a 95% CI of 56–94%).
Monitoring and Management During Treatment
Physical examination and evaluation of toxicity
was performed weekly. Complete blood count,
electrolytes, creatinine, and total protein were
determined weekly. Standard antiemetic prophylaxis
with 5HT3 antagonist prior to oxaliplatin infusion
was used. Adverse events were classiﬁed according
to the National Cancer Institute (NCI) Common
Toxicity Criteria (CTC) Version 2.0. Global quality
of life (QOL) assessment was evaluated weekly
during the chemoradiotherapy using a visual ana-
logue scale (VASQOL) in which in a single 10 cm
line anchored on the left with ‘‘worst’’ and on the
right with ‘‘best’’ for QOL.22 Dose-limiting toxicities
were deﬁned as white blood cell (WBC) and platelets
< 3.0 and < 100 · 109/L, respectively, before start
of the next treatment cycle with oxaliplatin after a
maximum delay of one week; diarrhea grade > 2;
oral mucositis grade >1; skin toxicity grade > 2
before start of next treatment cycle with capecita-
bine, despite a delay of dosing for 1 week; neuro-
sensory toxicity grade > 2 despite a delay in dosing
for 1 week; occurrence of any grade 4 toxicity; and
any event that would compromise the administra-
tion of radiotherapy.
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RESULTS
Patients Characteristics
Between June 2003 and December 2004, 22 pa-
tients with T3/T4 rectal cancer from four diﬀerent
centers were enrolled in the study. Patient charac-
teristics are shown in Table 1. All patients were
evaluable for toxicity during chemoradiation. One
patient was lost to follow-up after chemoradiation
(surgery was performed abroad). Therefore, 21 pa-
tients were evaluable for clinical outcome after sur-
gery. Twenty patients (91%) received the planned
dose of chemotherapy. All patients received the
planned dose of radiotherapy. The median follow-up
was 14 months.
Toxicity
At the ﬁrst oxaliplatin dose level of 85 mg/m2, one
patient experienced DLT (hospitalization for grade 3
nausea and grade 2 diarrhea). This dose level was
then expanded to six patients, and DLT was observed
in another patient (hospitalization for grade 3 diar-
rhea). Therefore, a dose of 85 mg/m2 oxaliplatin was
considered the MTD. In the additional 16 patients,
two more patients experienced grade 3 diarrhea.
Hand-foot syndrome, myelosuppression, and neuro-
toxicity were observed only in a minority of patients
and were of mild severity. The grade 3/4 toxicity data
are shown in Table 2.
Surgery
TME surgery was performed after a median of 47
days (range 4–8 weeks range in days) following the
completion of chemoradiation. Mean hospitalization
time was 14 days (range 9–95; 70% < 21 days). The
main surgical complications were: major bleeding (1),
rectal perforation (1), ureter lesion (1). Postsurgery
treatment related complications were seen in 12 pa-
tients with mild wound infections (6), wound dehi-
scences (2), (sub)ileus (4), rhabdomyolysis (1), and in
one patient a life-threatening multiorgan failure after
a perforation in an abcess located near the anus
praeter. Rhabdomyolysis is an unusual complication.
In this patient it was probably caused by the opera-
tion procedure and not by this specific procedure as
there were no other postoperative complications.
Three patients (15%) needed reoperation for perfo-
ration (1) and pelvic abscesses (2). The 60-day mor-
tality rate was nil.
Efﬁcacy
Twenty-one patients with a T3–T4 tumor based on
CT or MRI underwent surgery with 10 abdomino-
perineal resections (APRs) and 10 low anterior
resections (LARs); in one patient the tumor was not
resectable. A R0 resection was achieved in 17 patients
(81%, 95% CI 58–95%). A pCR was observed in 2
patients (10%, 95% CI 1–30%), and in one patient
(5%) the surgical specimen only showed minimal
microscopic disease. The postradiotherapeutic path-
ologic staging yielded in seven patients (33%; 95% CI
15–57%) a downstaging to pT0–T2. After a median
follow-up of 14 months, four patients have died due
to metastatic disease and one patient has experienced
a local recurrence.
Quality of Life
The VASQOL score was measured weekly during
chemoradiotherapy. The QOL decreased after 4
weeks treatment from 80% in week 4 to 60% in week
6 (p < .002, student-t test).
DISCUSSION
Based on the EORTC 22921 and FFCD 9203
phase III studies,11,13,23 preoperative chemoradiation
with 5FU and 45 Gy or higher is now considered to
be the standard of care for locally advanced rectal
cancer. In these studies, 5FU was given as a daily
bolus infusion in week 1 and 5. To improve on these
results, we tested the feasibility and efﬁcacy of the
addition of oxaliplatin to capecitabine in this com-
bined treatment strategy. Our recommended dose for
TABLE 1. Patient characteristics (n = 22)
Characteristics No.
Median age (years) 58
Range (years) 45–70
Men/Women 12/10
Performance status
0 3
1 19
Distance of tumor to anal verge (cm)
0–5 11
5–10 7
10–15 3
Unknown 1
T status
T3a 17
T4b 5
a T3 beyond the fascia recti.
b T4: into pelvic organs (1 ureter, 2 vagina, 2 prostate)
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TABLE 2. Toxicity in the study population (n = 22)
Study
Phase I Phase II
Dose oxaliplatin (number of patients)
85 mg/m2 (3) 85 mg/m2 (3) (22)
Toxicity grade (NCI
CTCV2.0)
Toxicity grade (NCI
CTCV2.0)
Toxicity grade (NCI
CTCV2.0)
3 4 3 4 3 4
Leukopenia – – – – – –
Neutropenia – – – – – –
Thrombopenia – – – – – –
Anemia – – – – – –
Diarrhea – – 1 – 4 –
Abdominal pain – – – – – –
Nausea 1 – – – – –
Mucositis – – – – – –
Neurotoxicity – – – – – –
TABLE 3. Locally advanced rectal cancer, recent neoadjuvant studies with ﬂuoropyrimidines and oxaliplatin in combination
with radiotherapy
Study
Design
(phase) Stage N
EBRT
(Gy) CT
R0
(%)
pCR
(%)
Toxicity grade 3–4 (%)
Total Diarrhea Myelotoxic
Preoperative radiotherapy vs. chemoradiotherapy (with 5 FU)
EORTC 2292111,23 III T3/T4 1011 45 – – 5 38a 17– 1–
45 5FU pre – 14 54– 34– 9–
FFCD 920313 III T3/T4 762 45 – 90 4 3 – –
45 5FU pre 91 12 15 – –
Bujko9 III T3/T4 316 5 · 5 – 87 1 3 – –
50.4 5FU pre 96 17 18 – –
Preoperative CRT with capecitabine
Kim30 II T3/T4/N+ 45 50.4 Cap 3 – 31 17 4 –
Dunst31/Glynne- Jones32 II T3/T4/N+ 98 50.4 + 5.4 Cap 1 – 4 22 4 10
Chau33 II T3+, low T3, N2 77 54 Cap 1b 99 24 4 deaths
Yerushalmi16 II T3/T4 (T2 10%) 46 50.4 5FU vs Cap 2 – 17 4
43 – 30 2
Preoperative CRT with 5 FU based chemotherapy and oxaliplatin
Gambacorta34 II T3 30 50 Tomox – 30 13 3 10
Gerard26 II T2/T3/T4 40 50.4 FU + Ox 1 – 15 18 5 3
Rodel35 II T3–4 32 50.4 Capox 4 79 19 16 8 0
Carraro36 II T3/T4 22 50.4 FU + Ox 2 – 14 – 27 14
Aschele25 I/II T3/T4/N+ 25 50.4 FU + Ox 3 89 28 24 16 4
Glynne-Jones32 I/II Unresectable 94 45 Capox 2 78 28 13 10 –
Machiels24 II T3/T4/N+ 40 45 Capox 1 83 14 – 30 –
Hospers (2006) This study I/II T3/T4 22 50.4 Capox 81 10 – 18 –
Cap 1: 825 mg/m2
2· daily, 7 days
Capox 1: Cap 825 2· daily,
Monday–Friday,
oxali 50 weekly
Tomox: raltitrexed 3, oxali 130,
day 1, 19, 38
Cap 2: 825 mg/m2
2· daily,
Monday–Friday
Capox 2: Cap 650
2· daily, 7 days,
oxali 130 per 2 weeks
FU + Ox 1: 5FU 350 daily,
Oxali 130 weekly, week 1 and 5
Cap 3: 825 mg/m2
2· daily,
14 days (2·)
Capox 3: Cap 825
2· daily, 7 days,
oxali 60 per 2 weeks
FU + Ox 2: 5FU 375/4 days,
Oxali 25/4 days, week 1 and 5
Capox 4: Cap 825 2· daily,
2 · 14 days, oxali 50,
day 1, 8, 22, 29
FU + Ox 3: 5FU 225 daily,
Oxali 60 weekly
a ‡Grade 2 toxicity.
b 12 weeks neoadjuvant CAPO.
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the phase II study was oxaliplatin 85 mg/m2 on day 1
and 29 plus capecitabine 1000 mg/m2 twice daily
during 14 days starting on day 1 and 25 in combi-
nation with radiotherapy at a total dose of 50.4 Gy.
In our phase I/II study, we found grade III diarrhea
in 19%, a R0 resection in 81%, downstaging to T0–2
in 33%, and a pCR in 10% of patients. Table 3
summarizes the studies with the addition of oxalipl-
atin to a ﬂuoropyrimidine (IV or orally) and radio-
therapy. These studies show a toxicity and efﬁcacy
proﬁle comparable to the results from our study.
Diarrhea generally occurred during the last 2 weeks
of chemoradiation, which was accompanied by a
signiﬁcant decrease in QOL. As shown in Table 2, the
addition of oxaliplatin increases the incidence of
toxicities when compared with the use of 5FU alone.
The observed postsurgical morbidity (mild wound
infections excluded), the reoperations and the median
hospitalization time in our study were 30%, 15%, and
14 days, respectively, and are comparable with other
studies.24–26
We found a similar eﬃcacy in pCR and R0 com-
pared to other studies (Table 3). However, compar-
ing the efﬁcacy of these regimes is hampered by a
number of technicalities. These comprise differences
in 1) staging techniques, 2) the determination of dis-
tance of the tumor to the endopelvic fascia, 3)
pathology techniques, and 4) the difference in interval
between neoadjuvant treatment and surgery. The
staging techniques used to deﬁne the locally advanced
stage of the primary tumor and lymph nodes are
clinical examination, CT, MRI, endoultrasound or
combinations, the use of ultrasmall particles of iron
oxide (USPIOs).27 These different staging techniques
may lead to variabilities in pretreatment staging and
therefore compromise the quantitation of downstag-
ing. Moreover, the tumor might be still visible on
posttreatment imaging, but it may have become
nonvital. The distance of the tumor to the endopelvic
fascia will inﬂuence the local recurrence rate. The
determination of a pCR and an R0 resection depends
on the sophistication of the pathology techniques
used, and the deﬁnition of a R0 resection (distance
tumor to resection or to CRM) is not uniform. In the
various clinical protocols, the time interval between
chemoradiotherapy and surgery is not standardized,
which may inﬂuence the degree of downstaging but
also the ultimate results of local cure. Therefore,
cross-study comparison should be interpreted with
caution. The end points used in this study are known
to have a different impact on clinical outcome: a pCR
is associated with a low local recurrence rate, and
prolonged DFS and is not signiﬁcantly related to the
cT and cN categories.28 R0 resection is known to be a
highly relevant prognostic factor.29 Comparing our
results on pCR and R0 to other oxaliplatin-contain-
ing studies, we found similar results; however, these
were also observed using monotherapy with 5FU or
capecitabine (Table 2). Therefore, it is yet unknown
whether the increased toxicity of adding oxaliplatin
to a ﬂuoropyrimidine in neoadjuvant chemoradiation
schedules results in a clinical beneﬁt for patients with
rectal cancer.
In conclusion, this multicenter study demonstrated
a neoadjuvant regimen with Capox-RT with an
acceptable acute toxicity proﬁle. Randomized phase
III studies with in the standard arm 5FU will be
necessary to show the true beneﬁt of this approach.
In such prospective studies, the standardization of the
staging technique (i.e., the distance of the tumor to
the endopelvic fascia), TME surgery, radiotherapy,
and pathology should minimize the inﬂuence of these
factors on the outcome.
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